Caris Life Sciences, INC

Caris Life Sciences shareholders successfully elected ten directors and ratified the appointment of Deloitte & Touche LLP as the independent auditor for 2026.

Caris Life Sciences has entered into a new $1.2 billion senior secured credit agreement to refinance existing debt and support future acquisitions.

Caris Life Sciences announced robust financial results for Q4 and full year 2025, driven by significant growth in molecular profiling services, and provided an optimistic 2026 revenue outlook of $1.0 billion to $1.02 billion.

Caris Life Sciences announced preliminary unaudited Q4 and full-year 2025 financial results, showcasing significant revenue and case volume growth.

Caris Life Sciences reported record third-quarter 2025 financial results, including a 113.4% revenue increase and positive net income, while raising full-year revenue guidance.

Caris Life Sciences, Inc. has amended its bylaws, requiring shareholders to beneficially own at least 3% of outstanding shares to initiate or maintain a derivative proceeding.

Caris Life Sciences reported strong Q1 2026 revenue growth to $216.2 million, driven by increased molecular profiling volumes.

Caris Life Sciences reports a significant revenue increase and a return to net income in Q3 2025, driven by strong molecular profiling services and a successful IPO.

Caris Life Sciences, a precision oncology pioneer, reported significant revenue growth in Q2 2025, driven by increased adoption of its molecular profiling services and a successful initial public offering.

Jon Halbert, a Director of Caris Life Sciences, Inc., purchased 68,000 shares of common stock on May 15, 2026 for $14.56 per share.

Director George Poste acquired 1,600 shares of Caris Life Sciences common stock as part of his 2026 board retainer compensation.

Director Jonathan Knowles acquired 1,600 shares of Caris Life Sciences, Inc. as part of his 2026 board retainer compensation.

J. Russel Denton, Senior Vice President at Caris Life Sciences, Inc., reported a transaction involving common stock, including shares withheld for tax payments.

Luke Thomas Power, Senior Vice President, Chief Financial Officer, and Chief Accounting Officer of Caris Life Sciences, Inc., reported a transaction involving the sale of 9,771 shares of common stock.

David Spetzler, President of Caris Life Sciences, Inc., reported a transaction involving the sale of 13,856 shares of common stock.

Caris Life Sciences schedules its 2026 Annual Meeting of Shareholders for June 4, 2026, to elect ten directors and ratify Deloitte & Touche LLP as its independent auditor.

Caris Life Sciences, a pioneer in AI-powered precision oncology, is launching its initial public offering to raise approximately $419.3 million, seeking to fund its growth and continued innovation despite a history of substantial net losses and negative cash flows.

Caris Life Sciences, a leading AI TechBio company specializing in precision oncology, is pursuing an initial public offering to fuel its rapid revenue growth and expand its innovative molecular profiling solutions, despite a history of substantial net losses and ongoing regulatory challenges.

Caris Life Sciences, a leading AI TechBio company specializing in precision oncology, has filed for an initial public offering to raise capital for continued innovation and market expansion of its comprehensive molecular profiling solutions, despite significant and ongoing net losses.

J.H. Whitney VI, L.P. and affiliated entities report beneficial ownership of 18,256,615 shares, representing 6.5% of Caris Life Sciences' common stock.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 10.8% in Caris Life Sciences Inc. as of March 31, 2026.

FMR LLC and Abigail P. Johnson have reported a 5.0% beneficial ownership stake in Caris Life Sciences Inc. common stock.

A group led by J.H. Whitney VI L.P. has reported beneficial ownership of 7.3% of Caris Life Sciences, Inc.'s common stock.

David D. Halbert and Caris Halbert, L.P. disclose significant beneficial ownership, collectively holding 44.1% of Caris Life Sciences, Inc. common stock.

TSSP Sub-Fund HoldCo, LLC and Alan Waxman have jointly disclosed beneficial ownership of 8.3% and 8.8% respectively, of Caris Life Sciences, Inc.'s Common Stock as of June 30, 2025.